Solvents and Parkinson disease: A systematic review of toxicological and epidemiological evidence

Toxicology and Applied Pharmacology

Volumn 266, Issue 3, 2013, Pages 345-355

  Lock, Edward A ^a   Zhang, Jing ^c   Checkoway, Harvey ^b  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; N Hexane; Neurotoxicology; Parkinson's disease; Parkinsonism; Solvents; Toluene; Trichloroethylene

Indexed keywords

DICHLOROMETHANE; DOPAMINE; METHANOL; SOLVENT; TETRACHLOROETHYLENE; TOLUENE; TRICHLOROETHYLENE;

CASE REPORT; CLINICAL FEATURE; DOPAMINE BRAIN LEVEL; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGICAL DATA; HUMAN; INTOXICATION; LONG TERM EXPOSURE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; OCCUPATIONAL EXPOSURE; PARKINSON DISEASE; PARKINSONISM; REVIEW; SUBSTANTIA NIGRA; SYSTEMATIC REVIEW; TOXICITY TESTING;

ANIMALS; DOPAMINERGIC NEURONS; ENVIRONMENTAL EXPOSURE; HUMANS; PARKINSON DISEASE, SECONDARY; SOLVENTS; SUBSTANTIA NIGRA; TRICHLOROETHYLENE; TWIN STUDIES AS TOPIC;

ANIMALIA;

EID: 84871890809     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.11.016     Document Type: Review

References (108)

1. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991, 337:1321-1327.
2. Albin R.L. Basal ganglia neurotoxins. Neurol. Clin. 2000, 18:665-680.
3. Anders M.W. Glutathione-dependent bioactivation of haloalkanes and haloalkenes. Drug Metab. Rev. 2004, 36:583-594.
4. Andersen M.E., Clewell H.J., Gargas M.L., MacNaughton M.G., Reitz R.H., Nolan R.J., McKenna M.J. Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. Toxicol. Appl. Pharmacol. 1991, 108:14-27.
5. Andres-Mateos E., Perier C., Zhang L., Blanchard-Fillion B., Greco T.M., Thomas B., Ko H.S., Sasaki M., Ischiropoulos H., Przedborski S., Dawson T.M., Dawson V.L. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14807-14812.
6. Ascherio A., Chen H., Weisskopf M.G., O'Reilly E., McCullough M.L., Calle E.E., Schwarzschild M.A., Thun M.J. Pesticide exposure and risk for Parkinson's disease. Ann. Neurol. 2006, 60:197-203.
7. Bale A.S., Barone S., Scott C.S., Cooper G.S. A review of potential neurotoxic mechanisms among three chlorinated organic solvents. Toxicol. Appl. Pharmacol. 2011, 255:113-126.
8. Berry C., La Vecchia C., Nicotera P. Paraquat and Parkinson's disease. Cell Death Differ. 2010, 17:1115-1125.
9. Betarbet R., Sherer T.B., Greenamyre J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol. 2005, 191(Suppl. 1):S17-S27.
10. Blandini F., Armentero M.T., Martignoni E. The 6-hyroxydopamine model: news from the past. Parkinsonism Relat. Disord. 2008, 14:S124-S129.
11. Braak H., Ghebremedhin E., Rüb U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
12. Bringmann G., God R., Feineis D., Wesemann W., Riederer P., Rausch W.D., Reichmann H., Sontag K.H. The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. J. Neural Transm. Suppl. 1995, 46:235-244.
13. Bull R.J. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. Environ. Health Perspect. 2000, 108(Suppl. 2):241-259.
14. Cai H., Guengerich F.P. Acylation of protein lysine's by trichloroethylene oxide. Chem. Res. Toxicol. 2000, 13:327-335.
15. Cannon J.R., Greenamyre J.T. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol. Sci. 2011, 124:225-250.
16. Caudle W.M., Guillot T.S., Lazo C.R., Miller G.W. Industrial toxicants and Parkinson's disease. Neurotoxicology 2012, 33:178-188.
17. Charles L.E., Burchfiel C.M., Fekedulegn D., Kashon M.L., Ross G.W., Sanderson W.T., Petrovitch H. Occupational exposures and movement abnormalities among Japanese-American men: the Honolulu-Asia Aging Study. Neuroepidemiology 2006, 26:130-139.
18. Chen J.C., Schneiderman J.F., Wortzman G. Methanol poisoning: bilateral putaminal and cerebellar cortical lesions on CT and MR. J. Comput. Assist. Tomogr. 1991, 15:522-524.
19. Chen P.C., Vargas M.R., Pani A.K., Smeyne R.J., Johnson D.A., Kan Y.W., Johnson J.A. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2933-2938.
20. Cintra A., Aguirre J.A., Andbjer B., Finnman U.B., Hagman M., Agnati L.F., Höglund C., Möller A., Fuxe K. Subchronic toluene exposure in low concentrations produces signs of reduced dysfunction in the 6-hydroxydopamine lesioned nigrostriatal dopaminergic system of the rat. Neurosci. Lett. 1999, 274:5-8.
21. Crocker S.J., Smith P.D., Jackson-Lewis V., Lamba W.R., Hayley S.P., Grimm E., Callaghan S.M., Slack R.S., Melloni E., Przedborski S., Robertson G.S., Anisman H., Merali Z., Park D.S. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. 2003, 23:4081-4091.
22. Cui M., Aras R., Christian W.V., Rappold P.M., Hatwar M., Panza J., Jackson-Lewis V., Javitch J.A., Ballatori N., Przedborski S., Tieu K. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8043-8048.
23. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
24. Davis L.E., Adair J.C. Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinsonian drugs. Mov. Disord. 1999, 14:520-522.
25. Dawson T., Dawson V. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
26. DeCaprio A.P., Kinney E.A., LoPachin R.M. Comparative covalent protein binding of 2,5-hexanedione and 3-acetyl-2,5-hexanedione in the rat. J. Toxicol. Environ. Health A 2009, 72:861-869.
27. DePalma G., Mozzoni P., Mutti A., Calzetti S., Negrotti A. Case-control study of interactions between genetic and environmental factors in Parkinson's disease. Lancet 1988, 352:1986-1987.
28. Dick F.D., De Palma G., Ahmadi A., Scott N.W., Prescott G.J., Bennett J., Semple S., Dick S., Counsell C., Mozzoni P., Haites N., Wettinger S.B., Mutti A., Otelea M., Seaton A., Söderkvist P., Felice A. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup. Environ. Med. 2007, 64:666-672. Geoparkinson Study Group, (673-80).
29. Eells J.T., Henry M.M., Lewandowski M.F., Seme M.T., Murray T.G. Development and characterization of a rodent model of methanol-induced retinal and optic nerve toxicity. Neurotoxicology 2000, 21:321-330.
30. Evans E.B., Balster R.L. CNS depressant effects of volatile organic solvents. Neurosci. Biobehav. Rev. 1991, 15:233-241.
31. Feany M.B., Anthony D.C., Frosch M.P., Zane W., De Girolami U. Two cases with necrosis and hemorrhage in the putamen and white matter. Brain Pathol. 2001, 11:121-122.
32. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
33. Feldman A.L., Johansson A.L., Nise G., Gatz M., Pedersen N.L., Wirdefeldt K. A 43-year prospective cohort study in men. Parkinsonism Relat. Disord. 2011, 17:677-682.
34. Filley C.M., Halliday W., Kleinschmidt-DeMasters B.K. The effect of toluene on the central nervous system. J. Neuropathol. Exp. Neurol. 2004, 63:1-12.
35. Finkelstein Y., Vardi J. Progressive parkinsonism in a young experimental physicist following long term exposure to methanol. Neurotoxicology 2002, 23:521-525.
36. Firestone J.A., Lundin J.I., Powers K.M., Smith-Weller T., Franklin G.M., Swanson P.D., Longstreth W.T., Checkoway H. Occupational factors and risk of Parkinson's disease: a population-based case-control study. Am. J. Ind. Med. 2010, 53:217-223.
37. Fornai F., Lazzeri G., Bandettini Di Poggio A., Soldani P., De Blasi A., Nicoletti F., Ruggieri S., Paparelli A. Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity. Ann. N. Y. Acad. Sci. 2006, 1074:84-89.
38. Gash D.M., Rutland K., Hudson M.L., Sullivan P.G., Bing G., Cass W.A., Pandya J.D., Liu M., Choi D.-Y., Hunter R.L., Gerhardt G.A., Smith C.D., Slevin J.T., Prince T.S. Trichloroethylene: parkinsonism and complex I mitochondrial neurotoxicity. Ann. Neurol. 2008, 63:184-192.
39. Geibprasert S., Gallucci M., Krings T. Addictive illegal drugs: structural neuroimaging. Am. J. Neuroradiol. 2010, 31:803-808.
40. Gerlach M., Xiao A.Y., Heim C., Lan J., God R., Feineis D., Bringmann G., Riederer P., Sontag K.H. 1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline increases extracellular serotonin and stimulates hydroxyl radical production in rats. Neurosci. Lett. 1998, 257:17-20.
41. Gibrat C., Saint-Pierre M., Bousquet M., Lévesque D., Rouillard C., Cicchetti F. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J. Neurochem. 2009, 109:1469-1482.
42. Goldberg N.R., Hampton T., McCue S., Kale A., Meshul C.K. Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning. J. Neurosci. Res. 2011, 89:1698-1706.
43. Goldman S.M. Trichloroethylene and Parkinson's disease: dissolving the puzzle. Expert Rev. Neurother. 2010, 10:835-837.
44. Goldman S.M., Quinlan P.J., Ross G.W., Marras C., Meng C., Bhudhikanok G.S., Comyns K., Korel M., Chade A.R., Kasten M., Priestley B., Chou K.L., Fernandez H.H., Cambi F., Langston J.W., Tanner C.M. Solvent exposures and parkinson disease risk in twins. Ann. Neurol. 2012, 71:776-784.
45. Gralewicz S., Dyzma M. Organic solvents and the dopaminergic system. Int. J. Occup. Med. Environ. Health 2005, 18:103-113.
46. Green T., Dow J., Foster J.R. Increased formic acid excretion and the development of kidney toxicity in rats following chronic dosing with trichloroethanol, a major metabolite of trichloroethylene. Toxicology 2003, 191:109-119.
47. Guehl D., Bezaed E., Dovero S., Boraud T., Bioulac B., Gross C. Trichloroethylene and parkinsonism: a human and experimental observation. Eur. J. Neurol. 1999, 6:609-611.
48. Hall G.M., Kirtland S.J., Baum H. The inhibition of mitochondrial respiration by inhalational anaesthetic agents. Br. J. Anaesth. 1973, 45:1005-1009.
49. Hester S.D., Johnstone A.F., Boyes W.K., Bushnell P.J., Shafer T.J. Acute toluene exposure alters expression of genes in the central nervous system associated with synaptic structure and function. Neurotoxicol. Teratol. 2011, 33:521-529.
50. Hewer C.L. Trichlorethylene. Anaesthesia 1975, 30:483-487.
51. Kim S.T., Son H.J., Choi J.H., Ji I.J., Hwang O. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease. Brain Res. 2010, 1306:176-183.
52. King M.D. Neurological sequelae of toluene abuse. Hum. Toxicol. 1982, 1:281-287.
53. Kochen W., Kohlmüller D., De Biasi P., Ramsay R. The endogeneous formation of highly chlorinated tetrahydro-beta-carbolines as a possible causative mechanism in idiopathic Parkinson's disease. Adv. Exp. Med. Biol. 2003, 527:253-263.
54. Kondo H., Huang J., Ichihara G., Kamijima M., Saito I., Shibata E., Ono Y., Hisanaga N., Takeuchi Y., Nakahara D. Toluene induces behavioral activation without affecting striatal dopamine metabolism in the rat: behavioral and microdialysis studies. Pharmacol. Biochem. Behav. 1995, 51:97-101.
55. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
56. Langston J., Irwin I., Ricaurte G. Neurotoxins, parkinsonism, and Parkinson's disease. Pharmacol. Ther. 1987, 32:19-49.
57. Lash L.H., Fisher J.W., Lipscomb J.C., Parker J.C. Metabolism of trichloroethylene. Environ. Health Perspect. 2000, 108(Suppl. 2):177-200.
58. Lazar R.B., Ho S.U., Melen O., Daghestani A.N. Multifocal central nervous system damage caused by toluene abuse. Neurology 1983, 33:1337-1340.
59. Lee K.W., Zhao X., Im J.Y., Grosso H., Jang W.H., Chan T.W., Sonsalla P.K., German D.C., Ichijo H., Junn E., Mouradian M.M. Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One 2012, 7:e29935.
60. Liu M., Choi D.-Y., Hunter R., Pandya J.D., Cass W.A., Sullivan P.G., Kim H.-C., Gash D.M., Bing G. Trichloroethylene induces dopaminergic neurodegeneration in Fischer 344 rats. J. Neurochem. 2010, 112:773-783.
61. Lolin Y. Chronic neurological toxicity associated with exposure to volatile substances. Hum. Toxicol. 1989, 8:293-300.
62. Martin I., Dawson V.L., Dawson T.M. Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics Hum. Genet. 2011, 12:301-325.
63. McDonnell L., Maginnis C., Lewis S., Pickering N., Antoniak M., Hubbard R., Lawson I., Britton J. Occupational exposure to solvents and metals and Parkinson's disease. Neurology 2003, 61:716-717.
64. Mortimer J.A., Borenstein A.R., Nelson L.M. Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis. Neurology 2012, 79:1174-1180.
65. NTP Technical report on the toxicology and carcinogenesis studies of chloral hydrate (CAS no. 302-17-0) in B6C3F1 mice (gavage studies). Natl. Toxicol. Program Tech. Rep. Ser. 2002, 502:1-197.
66. Ohlson C.G., Hogstedt C. Parkinson's disease and occupational exposure to organic solvents, agricultural chemicals and mercury-a case-referent study. Scand. J. Work Environ. Health 1981, 7:252-256.
67. Papageorgiou S.G., Karantoni E., Pandis D., Kouzoupis A.V., Kalfakis N., Limouris G.S. Severe dopaminergic pathways damage in a case of chronic toluene abuse. Clin. Neurol. Neurosurg. 2009, 111:864-867.
68. Park R.M., Schulte P.A., Bowman J.D., Walker J.T., Bondy S.C., Yost M.G., Touchstone J.A., Dosemeci M. Potential occupational risks for neurodegenerative diseases. Am. J. Ind. Med. 2005, 48:63-67.
69. Petersen M.S., Halling J., Bech S., Wermuth L., Weihe P., Nielsen F., Jørgensen P.J., Budtz-Jørgensen E., Grandjean P. Impact of dietary exposure to food contaminants on the risk of Parkinson's disease. Neurotoxicology 2008, 29:584-590.
70. Pezzoli G., Barbieri S., Ferrante C., Zecchinelli A., Fao V. Parkinsonism due to n-hexane exposure. Lancet 1989, 2:874.
71. Pezzoli G., Ricciardi S., Masotto C., Mariani C.B., Carenzi A. n-Hexane induces Parkinsonism in rodents. Brain Res. 1990, 531:355-357.
72. Pezzoli G., Canesi M., Antonini A., Righini A., Perbellini L., Barichella M., Mariani C.B., Tenconi F., Tesei S., Zecchinelli A., Leenders K.L. Hydrocarbon exposure and Parkinson's disease. Neurology 2000, 55:667-673.
73. Postuma R.B., Barone P., Burn D.J., Hawkes C.H., Oertel W., Ziemssen T. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov. Disord. 2012, 27:617-626.
74. Prockop L.D., Chichkova R.I. Carbon monoxide intoxication: an updated review. J. Neurol. Sci. 2007, 262:122-130.
75. Rea T.M., Nash J.F., Zabik J.E., Born G.S., Kessler W.V. Effects of toluene inhalation on brain biogenic amines in the rat. Toxicology 1984, 31:143-150.
76. Reddy N.J., Sudini M., Lewis L.D. Delayed neurological sequelae from ethylene glycol, diethylene glycol and methanol poisonings. Clin. Toxicol. (Phila.) 2010, 48:967-973.
77. Riederer P., Foley P., Bringmann G., Feineis D., Bruckner R., Gerlach M. Biochemical and pharmacological characterization of 1-trichloro-1,2,3,4-tetrahydro-β-carboline: a biologically relevant neurotoxin?. Eur. J. Pharmacol. 2002, 442:1-16.
78. Rissanen E., Paavilainen T., Virta J., Marttila R.J., Rinne J.O., Airas L. Carbon monoxide poisoning-induced nigrostriatal dopaminergic dysfunction detected using positron emission tomography (PET). Neurotoxicology 2010, 31:403-407.
79. Ritz B., Ascherio A., Checkoway H., Marder K.S., Nelson L.M., Rocca W.A., Ross G.W., Strickland D., Van Den Eeden S.K., Gorell J. Pooled analysis of tobacco use and risk of Parkinson disease. Arch. Neurol. 2007, 64:990-997.
80. Rubinstein D., Escott E., Kelly J.P. Methanol intoxication with putaminal and white matter necrosis: MR and CT findings. Am. J. Neuroradiol. 1995, 16:1492-1494.
81. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363:1783-1793.
82. Santamaria A.B., Cushing C.A., Antonini J.M., Finley B.L., Mowat F.S. State-of-the-science review: does manganese exposure during welding pose a neurological risk?. J. Toxicol. Environ. Health B Crit. Rev. 2007, 10:417-465.
83. Sauerbeck A., Hunter R., Bing G., Sullivan P.G. Traumatic brain injury and trichloroethylene exposure interact and produce functional, histological, and mitochondrial deficits. Exp. Neurol. 2012, 234:85-94.
84. Schwarting R.K., Sedelis M., Hofele K., Auburger G.W., Huston J.P. Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease. Neurotox. Res. 1999, 1:41-56.
85. Seidler A., Hellenbrand W., Robra B.P., Vieregge P., Nischan P., Joerg J., Oertel W.H., Ulm G., Schneider E. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996, 46:1275-1284.
86. Shahabi H.N., Andersson D.R., Nissbrandt H. Cytochrome P450 2E1 in the substantia nigra: relevance for dopaminergic neurotransmission and free radical production. Synapse 2008, 62:379-388.
87. Smargiassi A., Mutti A., De Rosa A., De Palma G., Negrotti A., Calzetti S. A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. Neurotoxicology 1998, 19:709-712.
88. Spencer P.S., Schaumburg H.H., Sabri M.I., Veronesi B. The enlarging view of hexacarbon neurotoxicity. Crit. Rev. Toxicol. 1980, 7:279-356.
89. Stengård K., Höglund G., Ungerstedt U. Extracellular dopamine levels within the striatum increase during inhalation exposure to toluene: a microdialysis study in awake, freely moving rats. Toxicol. Lett. 1994, 71:245-255.
90. Tanner C.M. Occupational and environmental causes of parkinsonism. Occup. Med. 1992, 7:503-513.
91. Tanner C.M., Ross G.W., Jewell S.A., Hauser R.A., Jankovic J., Factor S.A., Bressman S., Deligtisch A., Marrasm C., Lyons K.E., Bhudhikanok G.S., Roucoux D.F., Meng C., Abbott R.D., Langston J.W. Occupation and risk of parkinsonism: a multicenter case-control study. Arch. Neurol. 2009, 66:1106-1113.
92. Tephly T.R. Toxicity of methanol. Life Sci. 1991, 48:1031-1041.
93. Tillerson J.L., Miller G.W. Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. J. Neurosci. Methods 2003, 123:189-200.
94. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 1993, 61:1191-1206.
95. van der Mark M.B.M., Kromhout H., Nijssen P., Huss A., Vermeulen R. Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ. Health Perspect. 2012, 120:340-347.
96. von Euler G., Fuxe K., Benfenati F., Hansson T., Agnati L.F., Gustafsson J.A. Neurotensin modulates the binding characteristics of dopamine D2 receptors in rat striatal membranes also following treatment with toluene. Acta Physiol. Scand. 1989, 135:443-448.
97. von Euler G., Ogren S.O., Bondy S.C., McKee M., Warner M., Gustafsson J.A., Eneroth P., Fuxe K. Subacute exposure to low concentrations of toluene affects dopamine-mediated locomotor activity in the rat. Toxicology 1991, 67:333-349.
98. von Euler G., Ogren S.O., Li X.M., Fuxe K., Gustafsson J.A. Persistent effects of subchronic toluene exposure on spatial learning and memory, dopamine-mediated locomotor activity and dopamine D2 agonist binding in the rat. Toxicology 1993, 77:223-232.
99. von Euler M., Pham T.M., Hillefors M., Bjelke B., Henriksson B., von Euler G. Inhalation of low concentrations of toluene induces persistent effects on a learning retention task, beam-walk performance, and cerebrocortical size in the rat. Exp. Neurol. 2000, 163:1-8.
100. Wallace K.B., Eells J.T., Madeira V.M., Cortopassi G., Jones D.P. Mitochondria-mediated cell injury: symposium overview. Fundam. Appl. Toxicol. 1997, 38:23-37.
101. Wang J., Hokestra J.G., Zuo C., Cook T.J., Zhang J. Biomarkers of Parkinson's disease: current status and future. Drug Discov. Today 2012, 10.1016/jdrudis.2012.09.001. pii.S1359-6446(12) 00304-2.
102. Watts P.M., Riedl A.G., Douek D.C., Edwards R.J., Boobis A.R., Jenner P., Marsden C.D. Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neuroscience 1998, 86:511-519.
103. Williamson T.P., Johnson D.A., Johnson J.A. Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology 2012, 33:272-279.
104. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 2011, 26(Suppl. 1):S1-S58.
105. Wright Willis A., Evanoff B.A., Lian M., Criswell S.R., Racette B.A. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 2010, 34:143-151.
106. Yucel M., Takagi M., Walterfang M., Lubman D.I. Toluene misuse and long-term harms: a systematic review of the neuropsychological and neuroimaging literature. Neurosci. Biobehav. Rev. 2008, 32:910-926.
107. Zhang L., Gavin T., DeCaprio A.P., LoPachin R.M. Gamma-diketone axonopathy: analyses of cytoskeletal motors and highways in CNS myelinated axons. Toxicol. Sci. 2010, 117:180-189.
108. Zigmond M.J., Hastings T.G., Perez R.G. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity?. Parkinsonism Relat. Disord. 2002, 8:389-393.